Statistical and practical considerations for clinical evaluation of predictive biomarkers

Journal of the National Cancer Institute

Volumn 105, Issue 22, 2013, Pages 1677-1683

  Polley, Mei Yin C ^a   Freidlin, Boris ^a   Korn, Edward L ^a   Conley, Barbara A ^a   Abrams, Jeffrey S ^a   McShane, Lisa M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; INTERLEUKIN 6; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PACLITAXEL; PANITUMUMAB; PAZOPANIB; PLACEBO; TEMOZOLOMIDE; TUMOR MARKER;

CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CLINICAL EVALUATION; GLIOBLASTOMA; HAZARD RATIO; HUMAN; KIDNEY METASTASIS; LONG TERM SURVIVAL; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; METASTATIC COLORECTAL CANCER; MUTATION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN METHYLATION; QUALITATIVE RESEARCH; QUANTITATIVE STUDY; REVIEW; RISK ASSESSMENT; SAMPLE SIZE; SURVIVAL PREDICTION;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, RENAL CELL; DACARBAZINE; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; GLIOBLASTOMA; HUMANS; INDIVIDUALIZED MEDICINE; INTERLEUKIN-6; KIDNEY NEOPLASMS; LUNG NEOPLASMS; METHYLATION; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS; PREDICTIVE VALUE OF TESTS; PYRIMIDINES; QUINAZOLINES; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; SAMPLE SIZE; SULFONAMIDES; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84890541361     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt282     Document Type: Review

References (28)

1. Henry N, Hayes D. Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer. Oncologist. 2006;11(6):541-552.
2. Freidlin B, McShane L, Korn E. Randomized clinical trials with biomarkers: design issues. J Natl Cancer Inst. 2010;102(3):152-160.
3. US Food and Drug Administration (USFDA). Guidance on Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products. 2012. US FDA: Rockville, MD.
4. Freidlin B, Sun Z, Gray R, Korn EL. Phase III clinical trials that integrate treatment and biomarker evaluation. J Clin Oncol. 2013;31(25):3158- 3161.
5. Taube S, Clark G, Dancey J, McShane L, Sigman C, Gutman S. A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment. J Natl Cancer Inst. 2009;101(21):1453-1463.
6. Simon R, Paik S, Hayes D. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst. 2009;101(21):1446- 1452.
7. Jiang W, Freidlin B, Simon R. Biomarker-Adaptive threshold design: A procedure for evaluating treatment with possible biomarker-defined subset effect. J Natl Cancer Inst. 2007;99(13):1036-1043.
8. Taylor JMG, Ankerst DP, Andridge RR. Validation of biomarker-based risk prediction models. Clin Cancer Res. 2011;14(19):5977-5983.
9. Moore H, Kelly A, Jewell S, et al. Biospecimen reporting for improved study quality (BRISQ). J Proteome Res. 2011;10(8):3429-3438.
10. Peto R. Statistical aspects of cancer trials. In: Treatment of Cancer. Halnan K (ed.), 1982:867-871. London: Chapman and Hall.
11. Mok T, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New Engl J Med. 2009;361(10):947-957.
12. Pirker R, Pereira J, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (flex): An open-label randomised phase III trial. Lancet. 2009;373(9674):1525-1531.
13. Pirker R, Pereira J, von Pawel J, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: Analysis of data from the phase 3 flex study. Lancet Oncol. 2012;13(1):33-42.
14. Tran H, Liu Y, Zurita A, et al. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: A retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol. 2012;13(8):827-837.
15. Brugger W, Triller N, Blasinska-Morawiec M, et al. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol. 2011;29(31):4113-4120.
16. Peterson B, George S. Sample size requirements and length of study for testing interaction in a 1 x k factorial design when time-To-failure is the outcome. Control Clin Trials. 1993;14(6):511-522.
17. Vale C, Tierney J, Fisher D, et al. Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-Analysis. Cancer Treat Rev. 2012;38(6):618-625.
18. Khambata-Ford S, Harbison C, Hart L, et al. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(6):918-927.
19. O'Byrne K, Bondarenko I, Barrios C, et al. Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): data from the flex study. J Clin Oncol. 2009;27:408(Suppl 415):abstract 8007.
20. Stupp R, Mason W, van den Bent M, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med. 2005;352(10):987- 996.
21. Hegi M, Diserens A-C, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. New Engl J Med. 2005;352(10):997-1003.
22. Stupp R, Hegi M, Mason W, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459-466.
23. Weller M, Wick W, Hegi M, Stupp R, Tabatabai G. Should biomarkers be used to design personalized medicine for the treatment of glioblastomä Future Oncol. 2010;6(9):1407-1414.
24. McDonald K, Aw G, Kleihues P. Role of biomarkers in the clinical management of glioblastomas: what are the barriers and how can we overcome them? Front Neurol. 2012;3(188):1-8.
25. Shepherd F. Maintenance therapy comes of age for non-small-cell lung cancer, but at what cost? J Clin Oncol. 2011;29(31):4068-4070.
26. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25(1):118-145.
27. Koopmeiners J, Vogel R. Early termination of a two-stage study to develop and validate a panel of biomarkers. Stat Med. 2012;32(6):1027-1037.
28. The Center for Medical Technology Policy. Evaluation of Clinical Validity and Clinical Utility of Actionable Molecular Diagnostic Tests in Adult Oncology. Baltimore, MD: CMTP; 2013. http://www.cmtpnet.org/wp-content/uploads/ downloads/2013/05/CMTP-MDx-EGD05-01-2013.pdf. Accessed September 18, 2013.